Arrowhead Chief Sees Little Cost Increase Associated with Newly Acquired Peptide Tech | GenomeWeb

By Doug Macron

Arrowhead Research's top official last week assured investors that the company's acquisition of Alvos Therapeutics would not significantly impact its burn rate, which had already been markedly increased late last year when it acquired the RNA drug assets of Roche.

He also said that the deal is expected to give Arrowhead an edge in its longstanding effort to close a partnership with a bigger industry player, although he declined to provide any guidance on when such an arrangement might be struck.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.